(370 days)
Not Found
Not Found
No
The document describes a laser system with standard controls and no mention of AI/ML terms, image processing, or data sets for training/testing.
Yes.
The device is intended for the removal and reduction of unwanted hair, which is a therapeutic purpose.
No
This device is intended for the removal and reduction of unwanted hair, which is a therapeutic rather than a diagnostic purpose.
No
The device description clearly outlines hardware components such as a console, power supplies, optical deck, cooling system, keypad control panel, CRT, footswitch, and fiber optics, indicating it is a physical laser system, not software only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the "removal and reduction of unwanted hair" and "lightening and removal of unwanted body hair." This is a therapeutic or cosmetic procedure performed directly on the patient's body.
- Device Description: The description details a laser system that delivers energy to the patient's skin.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.) or providing information about a patient's health status based on such analysis. IVDs are used in vitro (outside the body) to examine specimens.
Therefore, the Orion Series Surgical Laser System, Crion Series Surgical Laser System, and Lyra Surgical Laser System, as described, are medical devices used for treatment, not for in vitro diagnostic purposes.
N/A
Intended Use / Indications for Use
The Orion Series Surgical Laser System (Q-Switched Nd:YAG configuration) is intended for the removal and reduction of unwanted hair.
The Crion Series Surgical Laser System and the Lyra Surgical Laser System are intended for the lightening and removal of unwanted body hair in Fitzgatrick Skin Ty I to VI using 1064 nm, Nd:YAG.
Product codes
GEX
Device Description
The Orion Series Surgical Laser System consists of a movable console containing power supplies, a treatment laser on a solid optical deck, and a cooling system to dissipate the heat generated by the system. A keypad control panel with CRT enables the user to control the laser system operating parameters. Surgical power is controlled via a footswitch. Laser power is emitted only when the footswitch is depressed. The delivery system is through fiber optics. Five configurations are currently available: 12W KTP only, 208 VAC; 12W KTP/30W Nd:YAG, 208 VAC; 20W KTP only, 208 VAC; 20W KTP/50W Nd:YAG, 208 VAC; 50W Nd:YAG only, 208 VAC.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
facial and non-facial anatomical areas.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
This study incorporated a multi-center, randomized, unblinded design with an active, parallel control. The primary objective of the study was to establish the safety and effectiveness of the Laserscope Q-Switched Nd.YAG laser in the reduction of hair density in facial and non-facial anatomical areas. This clinical study was conducted in support of the 510(k) submission.
Convenience sampling was used to enter 70 patients at three geographically dispersed investigational centers. The average patient age was 40.5 ± 8.7 years and the majority of the patients were female (79%). Describing the patient demographics entailed specifying each patient's Fitzgerald Classification, hair color, hair thickness, and hair weight. Fifty percent of the patients had a Fitzgerald Classification of 11, 71% of the patients had black hair, 67% of the patients had course hair, and 54% of the patient's had hair described as heavy.
The number of sites treated was fairly uniform across all sites with some weighting toward Study Center #3 (45%). Among the 70 patients, 139 sites were treated. All, but one patient, had two treatments each. The treatment sites were stratified by location (facial). Facial sites made up 34% of the treatments and non-facial sites accounted for 66% of the treatments.
All treatments were performed between June 8 and October 12, 1998. Laser energy settings ranged from 100 J/cm² to 153 J/cm². The lower energy settings were confined to facial treatments, while the higher energy settings were required for the non-facial treatments. Total lasing time was restricted to 30 seconds for all patients.
One primary safety and three secondary efficacy study objectives were specified in the study protocol. In terms of safety, only one adverse event (i.e., extended erythema and burning sensation resolved within 10 minutes of treatment) was reported at the time of treatment (1.4%). No adverse events or complications were reported beyond the time of treatment.
With regard to effectiveness, the investigator was to visually estimate percent reduction in hair density at each follow-up interval. The mean estimate of hair reduction was 26% at 7 days, 49% at 30 days, and 36% at 90 days post-treatment. When this analysis was further stratified by study center, it was found that Study Center #3 heavily influenced the lower estimates at 90 days post-treatment. Multivariate analysis of variance for longitudinal data revealed a significant difference in mean hair reduction over time and a significant study center effect. However, the location of the treatment had no impact on the estimates.
The patient was also queried as to her or his visual estimate of percent reduction in hair density at each follow-up interval. The patients' mean estimate of hair reduction was 33% at 7 days, 45% at 30 days, and 33% at 90 days post-treatment. The values and trends seen with the patients' estimates did not deviate greatly from that seen with the investigators. When this analysis was further stratified by study center, it was found that Study Center #3 again heavily influenced the lower estimates at 90 days post-treatment. The repeated measures multivariate analysis of variance revealed a significant difference in mean hair reduction over time, a significant study center effect, and a significant treatment location effect. These findings suggest great variance in patient estimates from center over time. Also, there was consistently lower hair reduction estimates reported across time for the non-facial sites, but the difference in estimates across time was not dependent upon the location of the treatment.
The last efficacy outcome was the patient satisfaction with treatment. The patients were asked to rank their treatments on a scale from 1 to 5 with one being worse than baseline and 5 being an excellent result. At seven days post-treatment, there was a 57% probability that the patients would rate their treatments as "Fair" or better. At 30 days post-treatment, there was an 89% probability that the patients would rate their treatments as "Fair" or better. At 90 days posttreatment, there was a 70% probability that the patients would rate their treatments as "Fair" or better.
A treatment success was based on the investigator estimate of ≥ 30% hair reduction and a patient satisfaction ranking of "Fair" or better. The overall success rates were 38% at seven days after treatment, 86% at 30 days after treatment, and 58% at 90 days after treatment. Although there was a significant study center effect and hair weight effect, very little difference was seen in overall success rates for facial and non-facial treatments.
Key Metrics
Mean estimate of hair reduction:
- Investigator: 26% at 7 days, 49% at 30 days, and 36% at 90 days post-treatment.
- Patient: 33% at 7 days, 45% at 30 days, and 33% at 90 days post-treatment.
Patient satisfaction with treatment (probability of rating "Fair" or better):
- 57% at 7 days post-treatment.
- 89% at 30 days post-treatment.
- 70% at 90 days post-treatment.
Overall success rates (investigator estimate of ≥ 30% hair reduction and patient satisfaction ranking of "Fair" or better):
- 38% at 7 days after treatment.
- 86% at 30 days after treatment.
- 58% at 90 days after treatment.
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.
(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.
0
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS LASERSCOPE ORION SERIES SURGICAL LASER SYSTEM For Reduction and Removal of Unwanted Hair
REGULATORY AUTHORITY
Safe Medical Device Act of 1990, 21 CFR 807.92
COMPANY NAME/CONTACT:
Paul Hardiman Laserscope 3052 Orchard Drive San Jose, CA 95134 Phone: 408-943-0636 FXA: 408-934-1454
DEVICE TRADE NAME
Orion Series Surgical Laser System
DEVICE COMMON NAME
Laser Instrument, Surgical, Powered
DEVICE DESCRIPTION:
The Orion Series Surgical Laser System consists of a movable console containing power supplies, a treatment laser on a solid optical deck, and a cooling system to dissipate the heat generated by the system. A keypad control panel with CRT enables the user to control the laser system operating parameters.
Surgical power is controlled via a footswitch. Laser power is emitted only when the footswitch is depressed. The delivery system is through fiber optics.
Five configurations are currently available:
12W KTP only, 208 VAC 12W KTP/30W Nd:YAG, 208 VAC 20W KTP only, 208 VAC 20W KTP/50W Nd:YAG, 208 VAC 50W Nd:YAG only, 208 VAC
Image /page/0/Picture/14 description: The image shows the number 000007 in a bold, sans-serif font. The numbers are all black and are set against a white background. The number seven is slightly separated from the other numbers.
1
Summary of Safety and Effectiveness, Page 2
DEVICE CLASSIFICATION:
The Orion Series Surgical Laser System has been classified as a Class II medical device by the OB/GYN, General, Plastic Surgery and ENT Device Advisory Panels.
PERFORMANCE STANDARDS
The Orion Series Surgical Laser System conforms with federal regulations and the performance standards 21 CFR 1040.10 and 1040.11 for medical laser systems.
INDICATIONS FOR USE STATEMENT
The Orion Series Surgical Laser System (Q-Switched Nd:YAG configuration) is intended for the removal and reduction of unwanted hair.
CLINICAL SUMMARY:
This study incorporated a multi-center. randomized, unblinded design with an active, parallel control. The primary objective of the study was to establish the safety and effectiveness of the Laserscope Q-Switched Nd.YAG laser in the reduction of hair density in facial and non-facial anatomical areas. This clinical study was conducted in support of the 510(k) submission.
Convenience sampling was used to enter 70 patients at three geographically dispersed investigational centers. The average patient age was 40.5 ± 8.7 years and the majority of the patients were female (79%). Describing the patient demographics entailed specifying each patient's Fitzgerald Classification, hair color, hair thickness, and hair weight. Fifty percent of the patients had a Fitzgerald Classification of 11, 71% of the patients had black hair, 67% of the patients had course hair, and 54% of the patient's had hair described as heavy.
The number of sites treated was fairly uniform across all sites with some weighting toward Study Center #3 (45%). Among the 70 patients, 139 sites were treated. All, but one patient, had two treatments each. The treatment sites were stratified by location (facial). Facial sites made up 34% of the treatments and non-facial sites accounted for 66% of the treatments.
All treatments were performed between June 8 and October 12, 1998. Laser energy settings ranged from 100 J/cm² to 153 J/cm². The lower energy settings were confined to facial treatments, while the higher energy settings were required for the non-facial treatments. Total lasing time was restricted to 30 seconds for all patients.
One primary safety and three secondary efficacy study objectives were specified in the study protocol. In terms of safety, only one adverse event (i.e., extended erythema and burning
Image /page/1/Picture/13 description: The image shows a sequence of numbers. The numbers are all zeros except for the last digit, which is an 8. The sequence of numbers is "000008".
7 Circ
2
Summary of Safety and Effectiveness, Page 3
sensation resolved within 10 minutes of treatment) was reported at the time of treatment (1.4%). No adverse events or complications were reported beyond the time of treatment.
With regard to effectiveness, the investigator was to visually estimate percent reduction in hair density at each follow-up interval. The mean estimate of hair reduction was 26% at 7 days, 49% at 30 days, and 36% at 90 days post-treatment. When this analysis was further stratified by study center, it was found that Study Center #3 heavily influenced the lower estimates at 90 days post-treatment. Multivariate analysis of variance for longitudinal data revealed a significant difference in mean hair reduction over time and a significant study center effect. However, the location of the treatment had no impact on the estimates.
The patient was also queried as to her or his visual estimate of percent reduction in hair density at each follow-up interval. The patients' mean estimate of hair reduction was 33% at 7 days, 45% at 30 days, and 33% at 90 days post-treatment. The values and trends seen with the patients' estimates did not deviate greatly from that seen with the investigators. When this analysis was further stratified by study center, it was found that Study Center #3 again heavily influenced the lower estimates at 90 days post-treatment. The repeated measures multivariate analysis of variance revealed a significant difference in mean hair reduction over time, a significant study center effect, and a significant treatment location effect. These findings suggest great variance in patient estimates from center over time. Also, there was consistently lower hair reduction estimates reported across time for the non-facial sites, but the difference in estimates across time was not dependent upon the location of the treatment.
The last efficacy outcome was the patient satisfaction with treatment. The patients were asked to rank their treatments on a scale from 1 to 5 with one being worse than baseline and 5 being an excellent result. At seven days post-treatment, there was a 57% probability that the patients would rate their treatments as "Fair" or better. At 30 days post-treatment, there was an 89% probability that the patients would rate their treatments as "Fair" or better. At 90 days posttreatment, there was a 70% probability that the patients would rate their treatments as "Fair" or better.
A treatment success was based on the investigator estimate of ≥ 30% hair reduction and a patient satisfaction ranking of "Fair" or better. The overall success rates were 38% at seven days after treatment, 86% at 30 days after treatment, and 58% at 90 days after treatment. Although there was a significant study center effect and hair weight effect, very little difference was seen in overall success rates for facial and non-facial treatments.
TECHNOLOGICAL CHARACTERISTICS
The Orion Series Surgical Laser System generates optical power by solid state Nd.YAG laser resonators. The system operates at wavelength (1064 nm). The near-infrared wavelentgh of
Image /page/2/Picture/8 description: The image shows a series of numbers and symbols. The top row displays "000009" in a bold, sans-serif font. Below this, there's a set of characters that appear to be ")(1", with the parentheses and the number 1 being more clearly defined than the other symbols.
3
Summary of Safety and Effectiveness, Page 4
this laser system is within the range (600 - 1100 nm) The primary tissue chromophores this laser system to within the rare hemoglobin and melanin. The absorption coefficient competing for lasseration and member by melanin, and the longer wavelength allow greater dermal penetration. The operating mode of the laser system is Q-Switched.
The short pulse duration of this laser system enables it to be used for selective rho short purce the intended target tissue has a thermal relaxation time of approximately 1 priororyou. " the pulse duration of the treatment laser light for this laser is in the manosecond range. The pulses are, therefore preferentially absorbed by pigmented structures in the targeted tissue, causing selective heating and thermal damage of the pigmented structures. The Q-Switched Nd: YAG systems' faster repetition rates (1 - 20 Hz Orion) enables the user to conduct faster treatment sessions.
The laser system delivers spot sizes in the 2 - 4 mm range. A specification table for the Orion Series Surgical Laser System and predicate device is found in Table II.
SUBSTANTIAL EQUIVALENCE DETERMINATION:
Since the Orion Series Surgical Laser System is substantially equivalent with respect to indications for use, materials, method of operation and physical construction to the predicate device, we believe they clearly meet the requirements for substantial equivalence according to 510(k) guidelines. Safety and effectiveness are reasonable assured, therefore justifying 510(k) clearance.
Image /page/3/Picture/6 description: The image shows the number 000010 in a bold, sans-serif font. The numbers are black against a white background. The numbers are evenly spaced and aligned horizontally.
4
SPECIFICATIONS
| SPECIFICATIONS | ORION SERIES SURGICAL LASER
SYSTEM- Q SWITCHED
CONFIGURATION |
|------------------------|--------------------------------------------------------------------|
| Laser Type | Nd:YAG/KTP |
| Wavelength | 1064 nm/532 nm |
| Operating Parameter | Q-Switched |
| Energy Per Pulse | 12.6 J/cm2 at 2 ms pulse width
(StarPulse) @ 1 mm spot size |
| Repetition Rate | 1020 Hz (StarPulse), single shot |
| Q-Switched Pulse Width | Nd:YAG: 150 ± 50 ns
KTP: 500 - 850 ns |
| Cooling | Closed cycle water to air heat
exchanger |
| Electrical Supply | 208V, single phase, 29A |
| Beam Delivery | Fiber Optic focusing handpiece; spot
sizes 1, 2, 4 mm |
| Weight | 380 pounds |
| Dimensions | 28" long, 18" wide, 48" high |
| Clinical Applications | Removal of dark tattoo ink, including
blue and black |
Image /page/4/Picture/2 description: The image shows the number 000011 in a bold, sans-serif font. The numbers are black and are set against a white background. There are two dots above the first zero.
5
OF HEALTH & HUMAN SERVICES-USA
VM
Public Health Service
MAR - 8 2000
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Mr. Paul H. Hardiman Manager, Regulatory and Clinical Affairs Laserscope 3052 Orchard Drive San Jose, California 95134
Re: K990718
Trade Name: Orion Series Surgical Laser System and Accessories Lyra Surgical Laser System and Accessories Regulatory Class: II Product Code: GEX Dated: February 7, 2000 Received: February 9, 2000
Dear Mr. Hardiman:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
6
Page 2 - Mr. Paul H. Hardiman
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4595. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
James E. Dillard III
James E. Dillard III Acting Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
7
INDICATIONS FOR USE STATEMENT
Page 1
510(k) Number:
K990718
Device Name:
ORION SERIES SURGICAL LASER SYSTEM AND ACCESSORIES LYRA SURGICAL LASER SYSTEM AND
:
て
ACCESSORIES
Indications for Use:
The Crion Series Surgical Laser System and the Lyra Surgical Laser System are intended for the lightening and removal of unwanted body hair in Fitzgatrick Skin Ty I to VI using 1064 nm, Nd:YAG.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use:
or Over The-Counter-Use
(per 21 CFR 801.109)
(Division Sign-Off)
Division of General Restorative Devices
510(k) Number K990718